A Once-Monthly Weight-Loss Injection? What MariTide's Phase 2 Data Actually Show

One of the most common frustrations I hear from patients on weekly injectable weight-loss medications is not about effectiveness — most patients are genuinely pleased with their results — but about the rhythm of weekly injections and, for some, the anxiety of never quite forgetting which day is injection day. So when I look at new obesity medications in development, dosing frequency is not a minor detail to me; it is directly tied to how well patients actually stick with treatment over years, not months. That is what makes maridebart cafraglutide, known by its development name MariTide, worth watching closely.

MariTide is being developed by Amgen, and it works differently from the GLP-1 medications most patients are now familiar with, like semaglutide and tirzepatide. Rather than being a small daily or weekly injected peptide, MariTide is a peptide-antibody conjugate — essentially, weight-loss peptides attached to an antibody fragment that dramatically extends how long the drug stays active in the body. This is what allows once-monthly, rather than once-weekly, dosing. Mechanistically, MariTide combines GLP-1 receptor agonism (the same core mechanism as semaglutide) with GIP receptor antagonism — blocking, rather than activating, the GIP receptor, which is the opposite approach to tirzepatide, which activates both GLP-1 and GIP receptors. Both strategies appear capable of producing substantial weight loss, which tells us there is likely more than one viable way to manipulate this hormonal pathway effectively, though the two approaches have not yet been compared head-to-head.

The results published in the New England Journal of Medicine come from a Phase 2 trial that studied two separate populations over one year. In adults with obesity but without diabetes, participants receiving MariTide lost between 12.3 and 16.2 percent of their body weight, depending on dose, compared to 2.5 percent in the placebo group. In adults with obesity and type 2 diabetes — a population that typically loses somewhat less weight on incretin-based therapies because of the underlying metabolic differences in this group — participants lost between 8.4 and 12.3 percent of body weight, compared to 1.7 percent with placebo, alongside meaningful improvements in blood sugar control, with hemoglobin A1c reductions of 1.2 to 1.6 percentage points.

The trial tested doses of 140, 280, and 420 milligrams, administered either every four weeks or every eight weeks in some cohorts, giving Amgen flexibility to determine the optimal dosing interval as the drug moves into Phase 3 testing under the MARITIME program.

I want to place these numbers in honest context relative to what is already available. Semaglutide (Wegovy) typically produces roughly 15 percent weight loss at maximum dose in trials, and tirzepatide (Zepbound) has shown up to roughly 20 percent or more in some studies. MariTide's Phase 2 results, in the 12 to 16 percent range for the non-diabetes population, are meaningful and clinically significant, but based on this early data, do not yet clearly exceed what tirzepatide has already demonstrated. What MariTide may offer instead is a different value proposition: convenience. A medication that requires 12 or 13 injections per year rather than 52 could meaningfully improve long-term adherence, reduce the psychological burden some patients describe around weekly dosing, and potentially lower the total cost and logistics of ongoing treatment, though pricing has not yet been determined since the drug remains investigational.

It is also worth being candid about what this data cannot yet tell us. This is Phase 2 data — meaningful, but still earlier-stage than the large Phase 3 trials that will determine cardiovascular outcomes, long-term safety over multiple years, and how MariTide performs against active comparators like tirzepatide rather than placebo alone. The detailed safety and tolerability profile from this trial has not been fully reported in what I have reviewed, and gastrointestinal side effects — the most common issue with this entire drug class — will need careful characterization, particularly since higher, less frequent doses can sometimes produce more pronounced side effects around the time of each injection.

My advice to patients who ask me about MariTide today: this is a drug to watch, not yet a drug to expect access to. If Phase 3 MARITIME trials confirm these results with an acceptable safety profile, once-monthly dosing could become a genuinely attractive option for patients who have struggled with the routine of weekly injections, or for whom convenience is a meaningful barrier to long-term treatment adherence. For now, semaglutide and tirzepatide remain the evidence-based, available options I recommend discussing with your physician if you are a candidate for medical weight management.

Source: "Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial," New England Journal of Medicine, 2026; Amgen.